Seelos Therapeutics Stock Fundamentals
Seelos Therapeutics fundamentals help investors to digest information that contributes to Seelos Therapeutics' financial success or failures. It also enables traders to predict the movement of Seelos OTC Stock. The fundamental analysis module provides a way to measure Seelos Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Seelos Therapeutics otc stock.
Seelos |
Seelos Therapeutics OTC Stock Return On Equity Analysis
Seelos Therapeutics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Seelos Therapeutics Return On Equity | -5.84 |
Most of Seelos Therapeutics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Seelos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Seelos Therapeutics has a Return On Equity of -5.842. This is 75.63% lower than that of the Pharmaceuticals sector and 83.98% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Seelos Therapeutics Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Seelos Therapeutics's current stock value. Our valuation model uses many indicators to compare Seelos Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Seelos Therapeutics competition to find correlations between indicators driving Seelos Therapeutics's intrinsic value. More Info.Seelos Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Seelos Therapeutics' earnings, one of the primary drivers of an investment's value.Seelos Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Seelos Therapeutics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Seelos Therapeutics could also be used in its relative valuation, which is a method of valuing Seelos Therapeutics by comparing valuation metrics of similar companies.Seelos Therapeutics is currently under evaluation in return on equity category among its peers.
Seelos Fundamentals
Return On Equity | -5.84 | |||
Return On Asset | -2.61 | |||
Profit Margin | 2.03 % | |||
Operating Margin | (8.35) % | |||
Current Valuation | 10.45 M | |||
Shares Outstanding | 581 K | |||
Shares Owned By Insiders | 0.49 % | |||
Shares Owned By Institutions | 4.46 % | |||
Number Of Shares Shorted | 170.89 K | |||
Price To Book | 15.10 X | |||
Price To Sales | 0.37 X | |||
Revenue | 2.2 M | |||
Gross Profit | (46.65 M) | |||
EBITDA | (40.44 M) | |||
Net Income | (37.88 M) | |||
Cash And Equivalents | 41.25 M | |||
Cash Per Share | 0.39 X | |||
Total Debt | 14.23 M | |||
Debt To Equity | 0.73 % | |||
Current Ratio | 3.60 X | |||
Book Value Per Share | (135.50) X | |||
Cash Flow From Operations | (23.91 M) | |||
Short Ratio | 0.14 X | |||
Earnings Per Share | 351.04 X | |||
Target Price | 120.0 | |||
Beta | 1.85 | |||
Market Capitalization | 743.68 K | |||
Total Asset | 5.42 M | |||
Retained Earnings | (252.63 M) | |||
Working Capital | (33.52 M) | |||
Net Asset | 5.42 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in income. Note that the Seelos Therapeutics information on this page should be used as a complementary analysis to other Seelos Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Other Consideration for investing in Seelos OTC Stock
If you are still planning to invest in Seelos Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Seelos Therapeutics' history and understand the potential risks before investing.
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |